HDAC7 Scaffolds GSK3β ‐Tau Interaction to Drive GSK3β Activation and Tau Pathology
Aging Cell · 2026-11 · 25 (11)
DOI: 10.1111/acel.70830 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, online erschienen am 10.11.2026. Verfasst von Shifeng Xiao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Brain Disease and Big Data Research Institute, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, Guangdong, China. Hauptthemen laut MEDLINE: Glycogen Synthase Kinase 3 beta, Histone Deacetylases, tau Proteins, Tauopathies. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions.
Abstract (Originalsprache)
Intraneuronal accumulation of hyperphosphorylated tau is a pathological hallmark of Alzheimer's disease (AD) and related tauopathies. Although dysregulation of both histone deacetylases (HDACs) and glycogen synthase kinase 3β (GSK‐3β) has been implicated in tau pathogenesis, whether and how they functionally interact to drive tau pathology remains unclear. Here, we identify HDAC7 as a critical scaffold that promotes GSK‐3β‐tau complex formation, leading to GSK‐3β activation and tau hyperphosphorylation in a tauopathy mouse model. HDAC7 is selectively upregulated in human tau‐bearing neurons. Neuronal overexpression of HDAC7 exacerbates tau hyperphosphorylation and cognitive deficits, accompanied by increased GSK‐3β kinase activity and protein levels both in vivo and in vitro. Mechanistically, HDAC7 scaffolds the direct interaction between GSK‐3β and tau independently of its deacetylase activity. Formation of the HDAC7‐GSK3β‐tau complex enables tau to promote GSK‐3β acetylation at lysine 15, which in turn stabilizes GSK‐3β protein and enhances its kinase activity. Conversely, neuronal deletion of HDAC7 reduces GSK‐3β protein levels and kinase activity, attenuates tau hyperphosphorylation, restores synaptic integrity, and rescues cognitive deficits in hTau‐expressing mice. Together, our findings propose a novel mechanism by which HDAC7 scaffolds GSK3β‐tau interaction to drive sustained GSK‐3β activation and tau pathology, highlighting reducing HDAC7 as a potential therapeutic strategy for AD and other tauopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Brain Disease and Big Data Research Institute, College of Life Sciences and Oceanography, Shenzhen University, Shenzhen, Guangdong, China.
- Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions, Shenzhen, China.
ORCID-Profile: Jinwang Ye
Förderung
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions
Zitieren
APA
Xiao, S., Wu, L., Qiao, W., Yue, R., Guo, X., Li, C., Tang, Y., & Ye, J. (2026). HDAC7 Scaffolds GSK3β ‐Tau Interaction to Drive GSK3β Activation and Tau Pathology. Aging Cell, 25(11). https://doi.org/10.1111/acel.70830
Vancouver
Xiao S, Wu L, Qiao W, Yue R, Guo X, Li C, et al. HDAC7 Scaffolds GSK3β ‐Tau Interaction to Drive GSK3β Activation and Tau Pathology. Aging Cell. 2026;25(11). doi:10.1111/acel.70830
BibTeX
@article{Xiao2026,
author = {Xiao, Shifeng and Wu, Lijuan and Qiao, Wenfei and Yue, Ruizhu and Guo, Xing and Li, Chengjia and Tang, Yingling and Ye, Jinwang},
title = {HDAC7 Scaffolds GSK3β ‐Tau Interaction to Drive GSK3β Activation and Tau Pathology},
journal = {Aging Cell},
year = {2026},
volume = {25},
number = {11},
doi = {10.1111/acel.70830}
}
EUVIMED